PATENT CLAIM ANALYSIS

Application Number: 16212723
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["544", "060000"]

Abstract:
The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Claim (Index 25):
The compound according to  claim 1 , wherein\n R 1  means \u2014H or \u2014CH 3 ; R 2  means \u2014CH 3 , \u2014CH 2 CH 3  or \u2014CH 2 \u2014C(H)(CH 3 ) 2 ; R 3  means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or monosubstituted with \u2014F; R 4  means \u2014H; \u2014C 1 -C 6 -alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, \u2550O, \u2014N(CH 3 ) 2  and \u2014O\u2014CH 3 ; or -cyclopropyl, -cyclobutyl, -cyclopentyl or -cyclohexyl, unsubstituted or monosubstituted with \u2014F, \u2014OH, \u2014CN or \u2014CH 3 , wherein said -cyclopropyl, -cyclobutyl, -cyclopentyl or -cyclohexyl is connected through \u2014CH 2 \u2014 or \u2014CH 2 CH 2 \u2014; -oxetanyl unsubstituted or monosubstituted with \u2014F, \u2014OH, \u2014CN or \u2014CH 3 , wherein said -oxetanyl is connected through \u2014CH 2 \u2014 or \u2014CH 2 CH 2 \u2014; X means \u2014O\u2014 or \u2014NR 6 \u2014; R 5  means \u2014H; \u2014C 1 -C 6 -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014O\u2014CH 3 , \u2014O\u2014(CH 2 \u2014CH 2 \u2014O) 1-10 \u2014H, \u2014O\u2014(CH 2 CH 2 \u2014O) 1-10 \u2014CH 3 , \u2014C(\u2550O)OH, \u2014C(\u2550O)OCH 3 , \u2014C(\u2550O)NH 2 , \u2014C(\u2550O)NHCH 3 , \u2014C(\u2550O)N(CH 3 ) 2 , \u2014OH, \u2014S(\u2550O)CH 3 , \u2014S(\u2550O) 2 CH 3 , unsubstituted \u2014C(\u2550O)-morpholinyl, \u2014NH\u2014C(\u2550O)\u2014CH 3 , \u2014N(CH 3 ) 2  and NH\u2014S(\u2550O) 2 \u2014CH 3 ; -cyclopropyl, -cyclobutyl, -cyclopentyl or -cyclohexyl, unsubstituted or monosubstituted with \u2014F, \u2014OH, \u2014CN or \u2014CH 3 , wherein said -cyclopropyl, -cyclobutyl, cyclopentyl or cyclohexyl is optionally connected through \u2014CH 2 \u2014 or \u2014CH 2 CH 2 \u2014; -heterocyclobutyl, -heterocyclopentyl, or -heterocyclohexyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014O\u2014CH 3 , \u2014O\u2014(CH 2 \u2014CH 2 \u2014O) 1-10 \u2014H, \u2014O\u2014(CH 2 CH 2 \u2014O) 1-10 \u2014CH 3 , \u2014C 1 -C 4 -alkyl, \u2014C(\u2550O)OH, \u2014C(\u2550O)OCH 3 , \u2014C(\u2550O)NH 2 , \u2014C(\u2550O)NHCH 3 , \u2014C(\u2550O)N(CH 3 ) 2 , \u2550O, \u2014OH, \u2014SCH 3 , \u2014S(\u2550O)CH 3 , \u2014S(\u2550O) 2 CH 3 , unsubstituted \u2014C(\u2550O)-morpholinyl, \u2014NH\u2014C(\u2550O)\u2014CH 3 , \u2014N(CH 3 ) 2  and NH\u2014S(\u2550O) 2 \u2014CH 3 ; wherein said -heterocyclobutyl, -heterocyclopentyl, or -heterocyclohexyl is optionally connected through \u2014CH 2 \u2014 or \u2014CH 2 CH 2 \u2014; -oxazolyl, -isoxazolyl, -pyrazolyl, -pyridinyl, -pyridazinyl, -pyrazinyl, -thiazolyl, -thiadiazolyl, -imidazolyl, -pyrimidinyl, or 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, Br, \u2014I, \u2014CN, \u2014OH, \u2014CH 3 , \u2014O\u2014CH 3 , \u2014C(\u2550O)OH, \u2014C(\u2550O)OCH 3 , \u2014C(\u2550O)NH 2 , \u2014C(\u2550O)NHCH 3 , \u2014C(\u2550O)N(CH 3 ) 2 , S(\u2550O)CH 3 , \u2014S(\u2550O) 2 CH 3  and \u2014S\u2014CH 3 , wherein said -oxazolyl, -isoxazolyl, -pyrazolyl, -pyridinyl, -pyridazinyl, -pyrazinyl, -thiazolyl, -thiadiazolyl, - imidazolyl, -pyrimidinyl, or 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine is optionally connected through \u2014CH 2 \u2014; or -phenyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, Br, \u2014I, \u2014CN, \u2014OH, \u2014CH 3 , \u2014O\u2014CH 3 , \u2014C(\u2550O)OH, \u2014C(\u2550O)OCH 3 , \u2014C(\u2550O)NH 2 , \u2014C(\u2550O)NHCH 3 , \u2014C(\u2550O)N(CH 3 ) 2 , S(\u2550O)CH 3 , \u2014S(\u2550O) 2 CH 3  and \u2014S\u2014CH 3 , wherein said -phenyl is optionally connected through \u2014CH 2 \u2014; in case X means NR 6 , R 6  means \u2014H or \u2014CH 3 ; or in case X means NR 6 , R 5  and R 6  together with the nitrogen atom to which they are attached form a -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -thiomorpholinyl, -thiomorpholinyl dioxide or -(methylsulfonyl)piperazinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2550O, \u2014OH, \u2014CH 2 \u2014OH, \u2014C(\u2550O)NH 2 , and \u2014S(\u2550O) 2 CH 3 , wherein said -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -thiomorpholinyl, -thiomorpholinyl dioxide or -(methylsulfonyl)piperazinyl is optionally condensed with an imidazole moiety, unsubstituted; and R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , and R 20  mean \u2014H.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 98.0
- Lexical Diversity: 1.11111
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12699451', '11994001', '12604691', '15125615', '15326138']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8580717365942678
- 35 USC 102 Novelty (BERT): 0.5497103275183666
- Combined Prediction Score: 0.8272355956866777
- Mean Citation Score: 400.58527
- Max Citation Score: 437.84778
- Similarity Product: 338.96451038496497

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test